<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04083599</url>
  </required_header>
  <id_info>
    <org_study_id>GCT1042-01</org_study_id>
    <nct_id>NCT04083599</nct_id>
  </id_info>
  <brief_title>GEN1042 Safety Trial in Subjects With Malignant Solid Tumors</brief_title>
  <official_title>A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genmab</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>BioNTech SE</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Genmab</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety of GEN1042 in patients with malignant solid tumors
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The trial is an open-label, multi-center, safety trial of GEN1042. The trial consists of two
      parts, a dose escalation (phase 1, first-in-human (FIH) and an expansion part (Phase 2a). The
      expansion part of the trial will be initiated once the Recommended Phase 2 Dose (RP2D) has
      been determined.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 17, 2019</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Limiting Toxicity (DLT)</measure>
    <time_frame>First Cycle (21 days)</time_frame>
    <description>Determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Events (AEs)</measure>
    <time_frame>Throughout study until the end of the safety follow-up period (2 months after last dose)]</time_frame>
    <description>Incidence of adverse events as assessed by CTCAE v5.0</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">126</enrollment>
  <condition>Malignant Solid Tumor</condition>
  <condition>Non Small Cell Lung Cancer</condition>
  <condition>Colorectal Cancer</condition>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>Treatment Administered</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GEN1042 will be administered every 21 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GEN1042</intervention_name>
    <description>GEN1042 will be administered intravenously every 21 days. The dose level will be determined by the starting dose and escalation steps in the trial.</description>
    <arm_group_label>Treatment Administered</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Dose Escalation:

        • Histologically or cytologically confirmed non-CNS solid tumor that is metastatic or
        unresectable and for whom there is no available standard therapy.

        Expansion:

        • Histologically or cytologically confirmed diagnosis of relapsed or refractory, advanced
        and/or metastatic melanoma, NSCLC, or CRC who are not anymore candidates for standard
        therapy

        Dose Escalation and Expansion:

          -  Measurable disease according to RECIST 1.1

          -  Eastern Cooperative Oncology Group (ECOG) 0-1

          -  Acceptable bone marrow and hematological, liver and renal functions

          -  Acceptable coagulation status

        Exclusion Criteria:

        Uncontrolled intercurrent illness, including but not limited to:

          -  Ongoing or active infection treated with intravenous anti-infective therapy less than
             2 weeks prior to first dose

          -  Symptomatic congestive heart failure, unstable angina pectoris or cardiac arrhythmia.

          -  Uncontrolled hypertension despite optimal medical management.

          -  Evidence of significant autoimmune disease suggesting risk for immune-related adverse
             events (irAEs).

          -  History of irAEs that led to treatment discontinuation of prior ICP inhibitor

          -  • History of chronic liver disease or evidence of hepatic cirrhosis.

          -  History of non-infectious pneumonitis that required steroids or currently has
             pneumonitis.

          -  History of organ allograft (except for corneal transplant) or autologous or allogeneic
             bone marrow transplant, or stem cell rescue within 3 months prior to the first dose of
             GEN1042.

          -  Serious, non-healing wound, skin ulcer (of any grade), or bone fracture.

          -  Any history of intracerebral arteriovenous malformation, cerebral aneurysm, or
             progressive brain metastases or stroke.

        Prior therapy:

          -  Radiotherapy within 14 days prior to first GEN1042 administration

          -  Treatment with an anti-cancer agent (within 21 days or after at least 5 half-lives of
             the drug, whichever is shorter), prior to GEN1042 administration.

          -  History of ≥ grade 3 allergic reactions to monoclonal antibody (mAb) therapy

          -  Toxicities from previous anti-cancer therapies that have not resolved
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Genmab A/S Trial Information</last_name>
    <phone>+4570202728</phone>
    <phone_ext>+4570202728</phone_ext>
    <email>clinicaltrials@genmab.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>cann.researchreferrals@scresearch.net</last_name>
    </contact>
    <investigator>
      <last_name>Melissa Johnson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet (Copenhagen University Hospital)</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Kristoffer Rohrberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Marsden NHS Foundation Trust</name>
      <address>
        <city>Sutton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dr. Juanita Lopez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>September 6, 2019</study_first_submitted>
  <study_first_submitted_qc>September 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2019</study_first_posted>
  <last_update_submitted>May 4, 2020</last_update_submitted>
  <last_update_submitted_qc>May 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

